JP2023549342A5 - - Google Patents

Info

Publication number
JP2023549342A5
JP2023549342A5 JP2023527473A JP2023527473A JP2023549342A5 JP 2023549342 A5 JP2023549342 A5 JP 2023549342A5 JP 2023527473 A JP2023527473 A JP 2023527473A JP 2023527473 A JP2023527473 A JP 2023527473A JP 2023549342 A5 JP2023549342 A5 JP 2023549342A5
Authority
JP
Japan
Prior art keywords
tumor
specific
immunogenic composition
specific neoantigens
sequence data
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023527473A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549342A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/058162 external-priority patent/WO2022098936A1/en
Publication of JP2023549342A publication Critical patent/JP2023549342A/ja
Publication of JP2023549342A5 publication Critical patent/JP2023549342A5/ja
Pending legal-status Critical Current

Links

JP2023527473A 2020-11-06 2021-11-05 個別化されたがんワクチンのためのネオアンチゲンの選択 Pending JP2023549342A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110711P 2020-11-06 2020-11-06
US63/110,711 2020-11-06
PCT/US2021/058162 WO2022098936A1 (en) 2020-11-06 2021-11-05 Selecting neoantigens for personalized cancer vaccine

Publications (2)

Publication Number Publication Date
JP2023549342A JP2023549342A (ja) 2023-11-24
JP2023549342A5 true JP2023549342A5 (https=) 2024-11-12

Family

ID=78695860

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527473A Pending JP2023549342A (ja) 2020-11-06 2021-11-05 個別化されたがんワクチンのためのネオアンチゲンの選択

Country Status (5)

Country Link
US (1) US20230197192A1 (https=)
EP (1) EP4241274A1 (https=)
JP (1) JP2023549342A (https=)
CN (1) CN116802738A (https=)
WO (1) WO2022098936A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022170067A1 (en) * 2021-02-05 2022-08-11 Amazon Technologies, Inc. Ranking neoantigens for personalized cancer vaccine
WO2025128926A1 (en) * 2023-12-13 2025-06-19 Amazon Technologies, Inc. Methods of identifying and treating individuals with elevated cancer risk
US20250197924A1 (en) 2023-12-15 2025-06-19 Amazon Technologies, Inc. Methods for selection and combination of sequencing results from biological samples for neoantigen scoring
WO2026072916A1 (en) 2024-09-30 2026-04-02 Amazon Technologies, Inc. Structural variant detection in circulating tumor dna
WO2026073127A1 (en) 2024-09-30 2026-04-02 Amazon Technologies, Inc. Dual assay to boost accuracy of detected actionable variants in liquid biopsy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
CN104885090A (zh) * 2012-10-09 2015-09-02 凡弗3基因组有限公司 肿瘤克隆性分析的系统和方法
ES2970865T3 (es) * 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
US10364468B2 (en) * 2016-01-13 2019-07-30 Seven Bridges Genomics Inc. Systems and methods for analyzing circulating tumor DNA
EP3652318A1 (en) * 2017-07-11 2020-05-20 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
US20200363414A1 (en) * 2017-09-05 2020-11-19 Gritstone Oncology, Inc. Neoantigen Identification for T-Cell Therapy
MX2021003654A (es) * 2018-09-27 2021-05-28 Nykode Therapeutics AS Metodo para seleccionar neoepitopes.
KR20240091046A (ko) * 2018-12-21 2024-06-21 바이오엔테크 유에스 인크. Hla 클래스 ii-특이적 에피토프 예측 및 cd4+ t 세포 특징화를 위한 방법 및 시스템

Similar Documents

Publication Publication Date Title
JP2023549342A5 (https=)
RU2019136762A (ru) Идентификация, производство и применение неоантигенов
JP2022524328A5 (https=)
JP2021514671A5 (https=)
JP2020532323A5 (https=)
JP2025143480A5 (https=)
JP2021529750A5 (https=)
JP2023100828A5 (https=)
EP2925349B1 (en) Tumor specific t-cell receptors
Guruprasad et al. The current landscape of single-cell transcriptomics for cancer immunotherapy
Fridman et al. The immune contexture in human tumours: impact on clinical outcome
ES2836273T3 (es) Método para el tratamiento del cáncer
ES3038443T3 (en) Individualized vaccines for cancer
JP2020200330A (ja) 癌のための個別化ワクチン
JP2022521486A5 (https=)
JP2019528769A5 (https=)
US10383931B2 (en) Peptides and combination of peptides for use in immunotherapy against cancers
CN108884468A (zh) 基于个性化递送载体的免疫疗法及其用途
JP2019514358A5 (https=)
JP7808695B2 (ja) タンパク質発現のためのmRNA及びそのための鋳型
JP2020532288A (ja) マイクロサテライト不安定性(msi)癌の予防及び治療のための共通腫瘍ネオアンチゲンをベースとした万能ワクチン
JP2020510426A5 (https=)
Baloria et al. In silico proteomic characterization of human epidermal growth factor receptor 2 (HER-2) for the mapping of high affinity antigenic determinants against breast cancer
US20220251544A1 (en) Methods and compositions for identifying neoantigens for use in treating and preventing cancer
CN105802909B (zh) 具有her2特异性tcr的t细胞制备物及其用途